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lipoprotein (HDL)-cholesterol including reduced sub-
class HDL2 particles and raised serum apolipoprotein
B concentrations. Xanthomata and xanthelasma may
relate to low lipoprotein lipase activity (10–12).
On a similar theme further questions that need
clarity are what about other skin ‘lipid’ stigmata and
cardiovascular risk? For example eruptive and tuber-
ous xanthomata are associated with chylomicron
syndrome and type III dyslipoproteinaemia, respec-
tively, and acanthosis nigricans and skin tags are pos-
sible features of insulin resistance states (13).
It is unlikely that we will ever know the Mona
Lisa’s carotid IMT but it makes sense as Bergman
(8) has suggested to determine plasma lipoprotein
levels in patients with xanthelasma and to assess
them for cardiovascular risk.
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EDITORIAL
Sexual health as a portal to men’s health: a problem
turned around into an opportunity
The prevalence of genitourinary problems and associ-
ated health concerns is high in middle-aged and
older men. A representative survey among men in
Australia over the age of 40 years indicated that 34%
reported one or more reproductive health disorder
(1). There is a belief that men, compared with
women, make less use of health services. This was
not conﬁrmed in the above study. About 88% of
men in this study had consulted a health professional
in the past 12 months, and health service utilisation
increased with age. However, the research showed
also that sexual and reproductive health problems
are often not explicitly discussed with a health pro-
fessional. Clinicians, while often seen as the primary
source of contact for reproductive health problems,
are often reluctant to initiate discussions with older
patients about sexual health (2). In our view many
opportunities to improve ageing men’s health are
thus not utilised. We propose a view here that geni-
tourinary (including sexual) health is a ‘portal’ to
men’s health.
Symptoms of genitourinary problems, such as
erectile dysfunction (ED) and lower urinary tract
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with the metabolic syndrome and type 2 diabetes
mellitus. The main components of the metabolic
syndrome are abdominal obesity, insulin resistance,
hypertension and hyperlipidaemia, all of which are
etiological factors of ED. The metabolic syndrome
and one of its consequences, type 2 diabetes mellitus,
are, in turn, associated with lower-than-normal
serum testosterone (T) levels (late onset hypogona-
dism). It is noteworthy that late onset hypogonadism
is frequently symptomatic. In men 45 years or older
surveyed in 130 primary care practices in the USA,
the presence of one or more symptoms occurred in
66% of men deemed hypogonadal based on their
T levels(4) .
The relationship between the metabolic syndrome
and type 2 diabetes mellitus and hypogonadism is
probably bidirectional. A large degree of obesity
and hyperinsulinism suppresses production of T,
but low T levels predict the metabolic syndrome
and type 2 diabetes mellitus. So, there is a close
relationship between ailments frequently occurring
in the ageing male (ED, LUTS, visceral obesity, car-
diovascular disease and diabetes mellitus) on the
one hand and hypogonadism on the other. This
close relationship probably indicates that late onset
hypogonadism is an expression of poor health, as
may be concluded from a recent study. Low testos-
terone levels were associated with increased mortal-
ity in male veterans (5), but this association was
not conﬁrmed in another study (6). This is as yet
not sufﬁcient evidence to treat all ageing men with
hypogonadism with T. Lifestyle changes are associ-
ated with improvement in sexual function in about
one-third of obese men with ED at baseline. Weight
loss and increased physical activity appeared to have
a favourable effect on erectile and endothelial func-
tions in obese men (7,8). The Massachusetts Male
Aging Study has estimated the frequency of ED
progression and remission among ageing men, and
assessed the relation of progression⁄remission to
demographics, socioeconomic factors, comorbidities
and modiﬁable lifestyle characteristics. Natural
remission and progression occur in a substantial
number of men with ED. Age and body mass index
were associated with progression and remission of
ED. The association of body mass index with remis-
sion and progression, and the association of smok-
ing and health status with progression, offer
potential avenues for facilitating remission and
delaying progression. The beneﬁts of such interven-
tions for overall men’s health may be far reaching
and conﬁrm the position that ED is a portal to
men’s health (9).
Treatment of ED when associated with hypogona-
dism may entail T administration (10) and these
interventional studies may provide an opportunity
to assess beneﬁts, yield, and justiﬁcation of T
administration on the closely interrelated ailments
of ED and the metabolic syndrome of which epide-
miologically hypogonadism is a correlate. The ﬁrst
results of T administration to elderly men show
that this may lead to improvement of both ED and
elements of metabolic syndrome (11) but the
administration of T to men with diabetes mellitus
is disappointing (12).
Shabsigh (13) have argued that ED can calculate
men’s health risks. Elements in the calculation of
health risks (hypertension, diabetes, angina or hyper-
lipidaemia) in men presenting with ED are: health
status on a scale of 1–7 (1 = excellent, 7 = poor),
waist size, severity of ED, presence⁄absence of a
sexual partner. The calculation produces scores of
ranges of 1–7. If the score is 1.5–2.5 = medium risk
(30–59% probability); ‡ 2.5 = high risk (‡ 60%
probability of having the condition) and < 1.5 = low
risk (< 30% probability).
In conclusion, physicians confronted with elderly
men with genitourinary problems are in a unique
position to address general health questions of the
patient. A holistic approach will not only beneﬁt the
presenting complaint but improve the general health
and well-being of the patient.
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